Skip to search formSkip to main contentSkip to account menu

boceprevir

Known as: 3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)-, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 
An orally bioavailable, synthetic tripeptide inhibitor of the nonstructural protein 3 and 4A complex (NS3/NS4A), with potential activity against… 
National Institutes of Health

Related topics

Related topics

7 relations
HCV NS3/4A Protease Inhibitors [MoA]Hepatitis Canalogs & derivativesboceprevir 200 MG Oral Capsule [Victrelis]

Broader (1)

Proline

Narrower (2)

SCH-503034Victrelis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Highly Cited
2014
Highly Cited
2014
Antiviral therapy of hepatitis C in 2014: do we need resistance testing?
Highly Cited
2014
Highly Cited
2014
Treating hepatitis C in lower-income countries.
With costs that may exceed $90,000 per course, effective new hepatitis C treatments seem beyond the reach of low- and middle… 
Highly Cited
2014
Highly Cited
2014
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.
Highly Cited
2013
Highly Cited
2013
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Review
2012
Review
2012
The role of resistance in HCV treatment.
Review
2012
Review
2012
Genomics and HCV infection: progression of fibrosis and treatment response.
Review
2011
Review
2011
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.
Review
2010
Review
2010
Boceprevir
Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C… 
Highly Cited
2008
Highly Cited
2008
Characterization of resistance mutations against HCV ketoamide protease inhibitors.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)